Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report report published on Sunday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 11.2 %

Shares of EGRX opened at $1.89 on Friday. The business’s 50-day moving average is $1.16 and its two-hundred day moving average is $1.08. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $6.37.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth approximately $453,000. DGS Capital Management LLC increased its holdings in Eagle Pharmaceuticals by 44.9% in the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 22,239 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Eagle Pharmaceuticals in the third quarter worth about $96,000. 85.36% of the stock is owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.